Neu-REFIX Beta glucan receives rare pediatric disease and orphan drug designations from the US FDA for treatment of Duchenne Muscular Dystrophy

Contributed by: Business Wire

Logo

Business Wire logo

Images

The parable of the lost sheep mirrors our journey to find a solution for Duchenne Muscular Dystrophy (DMD), a rare disease. Our global interdisciplinary team is fortunate to have been gifted with Neu REFIX, whose hidden potentials of beneficial immune modulation, we unravelled by extensive preclinical and clinical studies. This gives hope to DMD patients for its potentials in improving their quality of life by halting the disease progress. Like the shepherd when he found the lost sheep, our joy knew no bounds, when we got encouraging outcome in DMD research. Now on receiving orphan drug and rare paediatric disease designations from US FDA, while it’s time to rejoice, we have miles to go until it reaches every deserving patient after an approval, the final goal. We are open to collaborate with likeminded institutes to reach the goal. Further insights have revealed the potentials of Neu REFIX in Psoriasis, auto-immune diseases and in Multiple Sclerosis by gut microbiome reconstitution. (Graphic: Business Wire)
The parable of the lost sheep mirrors our journey to find a solution for Duchenne Muscular Dystrophy (DMD), a rare disease. Our global interdisciplinary team is fortunate to have been gifted with Neu REFIX, whose hidden potentials of beneficial immune modulation, we unravelled by extensive preclinical and clinical studies. This gives hope to DMD patients for its potentials in improving their quality of life by halting the disease progress. Like the shepherd when he found the lost sheep, our joy knew no bounds, when we got encouraging outcome in DMD research. Now on receiving orphan drug and rare paediatric disease designations from US FDA, while it’s time to rejoice, we have miles to go until it reaches every deserving patient after an approval, the final goal. We are open to collaborate with likeminded institutes to reach the goal. Further insights have revealed the potentials of Neu REFIX in Psoriasis, auto-immune diseases and in Multiple Sclerosis by gut microbiome reconstitution. (Graphic: Business Wire)
Business Wire embedded0

Tags

FDA
Health
Fitness & Nutrition
Research
Vitamins/Supplements
Science
Treatment of Duchenne Muscular Dystrophy

More Like This

An illustrative summary of the research outcome with Neu REFIX Beta glucan presents, several “Firsts” to its credit; (1) Oral consumption of a food supplement alone, without any other drugs, reducing skeletal muscle fibrosis in MDX mice, (2) In clinical studies, increase in plasma dystrophin which is considered of relevance to correction of vascular smooth muscle pathology, (3) Clinically evident beneficial reconstitution of gut microbiome in patients with DMD in a 45- days clinical study, (4) Reduction of myocardial fibrosis with neu REFIX alone in MDX mice, (5) Slowing down the progress of DMD pathology evident by 6MWT, NSAA and MRC in a six-month clinical study when Neu REFIX was consumed along with standard of care medication; Neu REFIX 1,3-1,6 Beta glucan is a food supplement without any therapeutic claims; Not a drug or remedy to any illness. Research findings not to be construed as medical advice. Neu REFIX doesn’t contain any of the commonly notified 28 allergens. (Graphic: Business Wire)

Neu REFIX β-glucan reduces muscle fibrosis in Duchenne muscular dystrophy MDX mice, in joint research with Dr. Yoshitsugu Aoki, NCNP, Tokyo, Japan.

PR Newswire associated0

U.S. FDA AWARDS BOTH RARE PEDIATRIC DISEASE AND ORPHAN DRUG DESIGNATIONS TO HG204, A CRISPR RNA-EDITING THERAPY, FOR THE TREATMENT OF MECP2 DUPLICATION SYNDROME

Astronauts during space missions, deep-sea researchers, high-altitude climbers, and workers exposed to radiation hazards, are highly prone to hastened process of aging and inflammaging, reflected by increase in NLR, Interleukin-6, gut dysbiosis and immune dysfunction. Going by earlier pre-clinical & clinical studies where oral consumption of Nichi BRITE and Neu REFIX beta-glucans have shown to safely and beneficially modify those biomarkers including reduction of D-Dimer and Ferritin, besides Neu REFIX standalone reducing skeletal muscle fibrosis are considered holding potentials for benefitting those undertaking expeditions in hostile conditions. Upon validation, they could be included in the guidelines as an ingredient especially for space foods. These exo-polysaccharide beta glucans produced by unique strains of Aureobasidium Pullulans are food supplements and not a drug or remedy for any illness. Research outcomes are not to be construed as medical advice.

Astronauts’ Health During Space Missions: Nichi BRITE and Neu REFIX Beta Glucans Could Benefit by Neutrophil-to-Lymphocyte Ratio, IL-6 Control, the Immune Biomarkers of Aging and Longevity

BioArctic receives Orphan Drug Designation for exidavnemab the US

Neuraptive Therapeutics Inc. Receives Orphan Drug Designation for its Lead Development Asset

Business Wire logo

Azafaros granted important regulatory designations and clearance by European authorities for global Phase 3 studies, to be initiated in 2025

Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan

PR Newswire associated0

Pierre Fabre Laboratories, committed to combating rare pediatric diseases via innovative therapies